Kodiak Sciences to Showcase KSI-101 Data at Major Retina Conferences

Kodiak Sciences Inc. (Nasdaq: KOD), a biotechnology pioneer specializing in retinal therapeutics, is gearing up to participate in two prominent scientific events: the 25th EURetina Congress and the Retina Society 58th Annual Scientific Meeting. These conferences, which will take place on September 5, 2025, in Paris, France, and September 13, 2025, in Chicago, Illinois, respectively, will focus on cutting-edge research surrounding KSI-101, specifically its application in treating macular edema secondary to inflammation, known as MESI.

Overview of KSI-101

KSI-101 is a groundbreaking therapeutic designed to address the needs of patients suffering from retinopathy characterized by substantial retinal fluid build-up due to inflammation. This novel drug combines two critical therapeutic targets: Interleukin-6 (IL-6) and Vascular Endothelial Growth Factor (VEGF). These factors play a significant role in the pathophysiology of various diseases resulting in macular edema, making KSI-101 potentially a revolutionary treatment option.

Upcoming Presentations

Dr. Charles Wykoff, an eminent figure in retinal research, will be presenting the Phase 1b APEX study results during both conferences. The title of his presentation is